Tripokin: A multi‐specific immunocytokine for cancer immunotherapy
Authors:
- 23 August 2024
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 156 (1) , 216-228
Abstract
Antibodies that target the tumor microenvironment can be used to deliver pro‐inflammatory payloads, such as cytokines. Cytokines are small proteins able to modulate the activity of the immune system, and antibody–cytokine fusion proteins have been tested in preclinical and clinical settings. In this study, we describe Tripokin, a novel multi‐specific fusion protein that combines interleukin‐2 and a single amino acid mutant of tumor necrosis factor. The two pro‐inflammatory payloads were fused to the L19 antibody, a clinical‐grade antibody against the extradomain B of fibronectin. The human payloads were used for clinical applications, while the corresponding murine cytokines were used for preclinical studies. The resulting fusion proteins were produced in mammalian cells and purified to homogeneity. The murine Tripokin product was well tolerated in tumor‐bearing mice at three doses of 30 μg in a 2‐day interval and promoted rapid tumor eradication in murine models, more efficiently than single‐agent immunocytokines. Tripokin induced rapid tumor necrosis and stimulated a robust immune response, impacting innate and adaptive immune pathways. In addition, the combination with immune checkpoint inhibitors further boosted the therapeutic efficacy of our molecule. Tripokin represents a promising clinical candidate for the simultaneous delivery of interleukin‐2 and tumor necrosis factor to neoplastic sites.Keywords
Funding Information
- Innosuisse - Schweizerische Agentur für Innovationsförderung (36371.1 IP‐LS)
This publication has 44 references indexed in Scilit:
- The present and future of immunocytokines for cancer treatmentCellular and Molecular Life Sciences, 2022
- A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patientsCancer Immunology, Immunotherapy, 2019
- The antibody‐based delivery of interleukin‐12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune checkpoint inhibitorsInternational Journal of Cancer, 2019
- Potentiation of PD-L1 blockade with a potency-matched dual cytokine–antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strainsCancer Immunology, Immunotherapy, 2018
- Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II studyCancer Immunology, Immunotherapy, 2015
- Therapy‐induced antitumor vaccination in neuroblastomas by the combined targeting of IL‐2 and TNFαInternational Journal of Cancer, 2010
- Immunocytokines for Cancer Immunotherapy2004
- Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancerCancer Immunology, Immunotherapy, 2002
- Tumor‐necrosis factor can enhance radio‐antibody uptake in human colon carcinoma xenografts by increasing vascular permeabilityInternational Journal of Cancer, 1993
- Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis.The EMBO Journal, 1991